m+Medelevator.RU
← Поиск публикаций
Human mutation · 2015

Rare Variants in PLD3 Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Cacace Rita, Van den Bossche Tobi, Engelborghs Sebastiaan, Geerts Nathalie, Laureys Annelies, Dillen Lubina, Graff Caroline, Thonberg Håkan, Chiang Huei-Hsin, Pastor Pau, Ortega-Cubero Sara, Pastor Maria A, Diehl-Schmid Janine, Alexopoulos Panagiotis, Benussi Luisa, Ghidoni Roberta, Binetti Giuliano, Nacmias Benedetta, Sorbi Sandro, Sanchez-Valle Raquel, Lladó Albert, Gelpi Ellen, Almeida Maria Rosário, Santana Isabel, Tsolaki Magda, Koutroumani Maria, Clarimon Jordi, Lleó Alberto, Fortea Juan, de Mendonça Alexandre, Martins Madalena, Borroni Barbara, Padovani Alessandro, Matej Radoslav, Rohan Zdenek, Vandenbulcke Mathieu, Vandenberghe Rik, De Deyn Peter P, Cras Patrick, van der Zee Julie, Sleegers Kristel, Van Broeckhoven Christine, Belgium Neurology (BELNEU) Consortium and the European Early-Onset Dementia (EU EOD) Consortium

Аннотация

Rare variants in the phospholipase D3 gene (PLD3) were associated with increased risk for late-onset Alzheimer disease (LOAD). We identified a missense mutation in PLD3 in whole-genome sequence data of a patient with autopsy confirmed Alzheimer disease (AD) and onset age of 50 years. Subsequently, we sequenced PLD3 in a Belgian early-onset Alzheimer disease (EOAD) patient (N = 261) and control (N = 319) cohort, as well as in European EOAD patients (N = 946) and control individuals (N = 1,209) ascertained in different European countries. Overall, we identified 22 rare variants with a minor allele frequency <1%, 20 missense and two splicing mutations. Burden analysis did not provide significant evidence for an enrichment of rare PLD3 variants in EOAD patients in any of the patient/control cohorts. Also, meta-analysis of the PLD3 data, including a published dataset of a German EOAD cohort, was not significant (P = 0.43; OR = 1.53, 95% CI 0.60-3.31). Consequently, our data do not support a role for PLD3 rare variants in the genetic etiology of EOAD in European EOAD patients. Our data corroborate the negative replication data obtained in LOAD studies and therefore a genetic role of PLD3 in AD remains to be demonstrated.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты